Uniqure Crashes To Six-Year Low On Muddy Results For Huntington's Gene TherapyInvestors Business Daily • 06/21/23
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's DiseaseGlobeNewsWire • 06/21/23
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapyGlobeNewsWire • 06/20/23
CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia BPRNewsWire • 06/20/23
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 MillionGlobeNewsWire • 05/15/23
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 05/09/23
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual MeetingGlobeNewsWire • 05/02/23
uniQure Announces 2022 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 02/27/23
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)GlobeNewsWire • 02/23/23
CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)PRNewsWire • 02/23/23
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia BGlobeNewsWire • 02/21/23
First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European CommissionPRNewsWire • 02/20/23
uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1GlobeNewsWire • 01/31/23
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia BGlobeNewsWire • 12/16/22